
Opinion|Videos|October 7, 2024
PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials
Author(s)Neal Shore, MD, FACS
Key Takeaways
Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the crucial role of PSMA PET imaging in determining treatment suitability.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
4
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
5









